BeiGene
BGNE
$325.59
Share price
0.49%
Change (1 day)
22.01%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
BeiGene (BGNE) - Cash on Hand
Cash on Hand as of September 2024 : NZ$4.76 Billion
According to BeiGene
's latest financial reports the company has NZ$4.76 Billion in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
BeiGene - Cash on Hand chart (from 2014 to 2024)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | NZ$5.01 B | -29.72% |
| 2022-12-31 | NZ$7.14 B | -26.28% |
| 2021-12-31 | NZ$9.68 B | 50.31% |
| 2020-12-31 | NZ$6.44 B | 341.71% |
| 2019-12-31 | NZ$1.45 B | -45.06% |
| 2018-12-31 | NZ$2.65 B | 125.21% |
| 2017-12-31 | NZ$1.17 B | 121.87% |
| 2016-12-31 | NZ$0.53 B | 262.02% |
| 2015-12-31 | NZ$0.14 B | 159.12% |
| 2014-12-31 | NZ$56.66 M | 1085.99% |
| 2013-12-31 | NZ$4.77 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 | NZ$28.89 M | -99.39% | 🇺🇸 USA |
 | NZ$0.76 B | -84.01% | 🇺🇸 USA |